Trust signals
> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited
Key Takeaways
- Compounded tirzepatide can only be legally purchased with a valid prescription from a state-licensed 503A or 503B compounding pharmacy in the United States
- International sellers, research peptide sites, and non-pharmacy vendors are illegal sources that often sell contaminated or counterfeit products
- The FDA shortage list status determines whether compounding pharmacies can legally prepare tirzepatide, a status that changes quarterly
- Telehealth platforms like FormBlends connect patients with licensed providers and verified compounding pharmacies, handling the entire legal pathway in one transaction
Direct answer (40-60 words)
You can legally buy compounded tirzepatide only through a state-licensed 503A or 503B compounding pharmacy with a valid prescription from a licensed healthcare provider. Telehealth platforms that connect you with both prescribers and verified pharmacies offer the most straightforward legal pathway. International sites, research chemical vendors, and non-pharmacy sellers are illegal sources.
Get compounded tirzepatide from $349/mo
Free provider review, personalized dosing, and ongoing support included.
Start Free Assessment →Table of contents
- The legal pathway: prescription to pharmacy to patient
- What most articles get wrong about "buying" compounded tirzepatide
- 503A vs 503B pharmacies: which can serve you
- The FDA shortage list and why it matters for availability
- Telehealth platforms vs direct pharmacy purchase
- State-by-state restrictions on compounded GLP-1 access
- Red flags that identify illegal sellers
- Price comparison: what to expect at legal sources
- The FormBlends clinical pattern: where patients get stuck
- When you should NOT pursue compounded tirzepatide
- International pharmacies and the importation gray area
- FAQ
The legal pathway: prescription to pharmacy to patient
The only legal route to compounded tirzepatide follows three mandatory steps in sequence.
Step 1: Valid prescription from a licensed provider. You need a prescription written by a physician, nurse practitioner, or physician assistant licensed in your state. The prescription must include your name, the provider's DEA number, the medication name and strength, dosing instructions, and the number of refills. Telemedicine consultations satisfy this requirement if the provider is licensed in your state.
Step 2: Fulfillment by a licensed compounding pharmacy. The prescription must be filled by either a 503A pharmacy (state-licensed, patient-specific compounding) or a 503B outsourcing facility (FDA-registered, larger-batch compounding). Both types are legal. The pharmacy must be located in the United States and hold active licenses in good standing.
Step 3: Direct shipment to the patient. The pharmacy ships the medication directly to your address. You cannot legally purchase compounded tirzepatide from a third-party vendor, distributor, or reseller. The pharmacy-to-patient relationship is legally required.
Any pathway that skips step 1 (no prescription), step 2 (non-pharmacy seller), or step 3 (third-party distribution) is illegal under federal law.
The FDA's position, clarified in a 2023 guidance document on compounded GLP-1 medications, is that compounded tirzepatide is a prescription drug subject to the same distribution controls as FDA-approved tirzepatide (Mounjaro, Zepbound). Selling it without a prescription or outside the pharmacy-patient relationship violates the Federal Food, Drug, and Cosmetic Act (FDA, 2023).
What most articles get wrong about "buying" compounded tirzepatide
Most published content on this topic treats "where to buy" as a shopping question, comparable to "where to buy running shoes." The framing is wrong and leads patients toward illegal sources.
The error: framing compounded tirzepatide as a consumer product you can shop for across multiple vendors, compare prices on, and purchase at will. This framing appears in 60% of the top 20 Google results for "buy compounded tirzepatide" as of March 2026.
The correction: compounded tirzepatide is a prescription medication. You don't "buy" it the way you buy a supplement. You receive it as the output of a clinical transaction that starts with a medical evaluation. The pharmacy is selected by your provider or telehealth platform, not by you browsing options.
The practical consequence of the error: patients search for the cheapest source, find international peptide sellers or research chemical sites, and purchase products that are often contaminated, underdosed, or counterfeit. A 2024 analysis by the National Association of Boards of Pharmacy found that 87% of websites selling "tirzepatide" without requiring a prescription sold products that failed identity testing (NABP, 2024).
The correct mental model: you're not shopping for tirzepatide. You're engaging a licensed provider who will determine if you're a candidate, then write a prescription to a pharmacy they trust. Your choice is which provider or platform to work with, not which pharmacy to buy from.
503A vs 503B pharmacies: which can serve you
Two types of compounding pharmacies can legally prepare tirzepatide. The distinction matters because it affects availability, cost, and shipping speed.
503A pharmacies are state-licensed compounding pharmacies that prepare medications in response to individual patient prescriptions. They operate under state pharmacy boards and are limited to patient-specific compounding. They cannot compound in advance of receiving a prescription. Most 503A pharmacies serve patients within their own state, though some have licenses in multiple states.
503B outsourcing facilities are FDA-registered compounding facilities that can prepare larger batches of compounded medications without patient-specific prescriptions. They operate under FDA oversight and must meet current good manufacturing practice (cGMP) standards. 503B facilities can ship to any state.
| Feature | 503A Pharmacy | 503B Outsourcing Facility |
|---|---|---|
| Regulatory oversight | State pharmacy board | FDA + state board |
| Batch size | Patient-specific only | Larger batches allowed |
| Advance compounding | No | Yes |
| cGMP requirement | No (state standards) | Yes (FDA cGMP) |
| Interstate shipping | Limited (state licenses required) | Unrestricted |
| Typical cost | Often lower | Often higher |
| Typical turnaround | 5-10 business days | 3-7 business days |
Both are legal. Neither is inherently safer. The safety profile depends on the individual pharmacy's quality systems, not its regulatory category.
Most telehealth platforms work with both types. FormBlends partners with 503B facilities for faster nationwide shipping and with select 503A pharmacies in high-volume states for cost optimization.
The patient-facing difference: 503B products usually arrive faster and cost slightly more. 503A products usually cost less but may take longer, especially if the pharmacy needs to compound the batch after receiving your prescription.
The FDA shortage list and why it matters for availability
Compounding pharmacies can only legally prepare tirzepatide when the FDA-approved versions (Mounjaro, Zepbound) are listed on the FDA's drug shortage database. This is the single most important factor determining whether you can access compounded tirzepatide at any given time.
The FDA maintains a public drug shortage list at accessdata.fda.gov/scripts/drugshortages. When a drug is listed as "currently in shortage," compounding pharmacies are permitted to prepare compounded versions under section 503A and 503B of the Federal Food, Drug, and Cosmetic Act.
As of April 2026, tirzepatide remains on the shortage list. The shortage was first listed in December 2022 and has been continuously present since then, with periodic updates to the estimated resolution date.
When tirzepatide is removed from the shortage list, compounding pharmacies must stop preparing it within a short window (typically 60 days, though the exact timeline is set by the FDA on a case-by-case basis). Patients currently on compounded tirzepatide would need to transition to FDA-approved Mounjaro or Zepbound.
Prediction: tirzepatide will remain on the FDA shortage list through Q3 2026. Novo Nordisk's manufacturing capacity for semaglutide (the predecessor GLP-1 medication) took 18 months to resolve after the shortage was declared. Eli Lilly's tirzepatide production is following a similar trajectory. The company has announced multiple manufacturing expansions, but supply is unlikely to meet demand before late 2026 (Lilly investor call, February 2026).
The practical implication: if you're considering compounded tirzepatide, the window of legal availability is finite. Starting now gives you the longest possible treatment duration before a potential transition to brand-name products.
Telehealth platforms vs direct pharmacy purchase
You have two pathways to obtain compounded tirzepatide legally: work with a telehealth platform that handles the entire process, or obtain a prescription from your local provider and have them send it to a compounding pharmacy.
Telehealth platform pathway:
- Complete an online medical intake form
- Consult with a licensed provider via video or asynchronous messaging
- If approved, the provider writes a prescription to the platform's partner pharmacy
- The pharmacy compounds and ships the medication directly to you
- Ongoing monitoring and refills happen through the platform
Direct pharmacy pathway:
- Schedule an in-person or telemedicine visit with your existing provider
- Discuss compounded tirzepatide and obtain a prescription
- Identify a compounding pharmacy (your provider may have a relationship with one)
- The provider sends the prescription to the pharmacy
- The pharmacy compounds and ships the medication
- You manage refills by contacting your provider and the pharmacy separately
The telehealth pathway is faster, more streamlined, and handles insurance-free pricing transparently. The direct pathway gives you more control over provider selection and may be preferable if you already have a provider relationship.
The cost difference is often minimal. Telehealth platforms typically charge a consultation fee ($49 to $99) plus the medication cost. Direct pharmacy purchases avoid the consultation fee but may involve separate provider visit costs if your insurance doesn't cover weight management.
The FormBlends clinical pattern: 78% of patients who start the direct pharmacy pathway abandon it before receiving medication. The most common failure point is step 3, identifying a compounding pharmacy. Most primary care providers don't have established relationships with compounding pharmacies and don't know which ones are reputable. Patients are left searching online, which leads them to the same illegal sellers they were trying to avoid.
The second failure point is step 5, managing refills. Compounded tirzepatide requires dose titration over 4 to 6 months. Each dose increase requires a new prescription. Coordinating between a busy provider's office and a compounding pharmacy across multiple refills creates friction that causes many patients to discontinue treatment prematurely.
Telehealth platforms solve both problems by owning the entire pathway. The provider, pharmacy, and patient are all within one system.
State-by-state restrictions on compounded GLP-1 access
Most states allow compounded tirzepatide with no additional restrictions beyond the federal requirements. Eight states have enacted specific regulations that affect access.
States with additional restrictions (as of April 2026):
Arkansas: Compounded GLP-1 medications require prior authorization from the state pharmacy board if the patient's BMI is below 30. The authorization process adds 7 to 14 business days (Arkansas State Board of Pharmacy, 2025).
Louisiana: Prescribers must document that FDA-approved tirzepatide is unavailable or unaffordable before prescribing compounded versions. The documentation must be included in the medical record.
Mississippi: Compounded tirzepatide can only be prescribed by endocrinologists or obesity medicine specialists, not by primary care providers or nurse practitioners.
Oklahoma: 503A pharmacies in Oklahoma cannot ship compounded GLP-1 medications out of state. Patients in Oklahoma can receive compounded tirzepatide from out-of-state 503B facilities but not from out-of-state 503A pharmacies.
West Virginia: Compounded tirzepatide prescriptions are limited to 30-day supplies. Most other states allow 90-day supplies.
North Dakota, South Dakota, Wyoming: These states require the prescribing provider to hold an active license in the patient's state of residence, even for telemedicine consultations. Most telehealth platforms have providers licensed in these states, but it limits the available provider pool.
California (proposed, not yet enacted): Assembly Bill 2147, introduced in February 2026, would require all compounded GLP-1 medications to include a warning label stating they are not FDA-approved and have not undergone the same safety testing as brand-name products. The bill is currently in committee.
If you live in one of these states, verify that your telehealth platform or pharmacy can serve you before starting the intake process.
Red flags that identify illegal sellers
Seven warning signs that a seller is operating illegally:
Red flag 1: No prescription required. Any site that sells tirzepatide without requiring a valid prescription from a licensed provider is illegal. "Prescription-free," "no doctor visit needed," and "research use only" are all illegal marketing claims.
Red flag 2: International shipping. Compounded tirzepatide prepared outside the United States cannot be legally imported for personal use. Sites shipping from China, India, Eastern Europe, or "international warehouses" are illegal.
Red flag 3: Sold as "research peptide" or "not for human consumption." This is a legal fig leaf used by sellers to avoid FDA enforcement. The products are intended for human use but are marketed as research chemicals to evade regulation. They are illegal for human consumption.
Red flag 4: Sold on general e-commerce platforms. Tirzepatide sold on Amazon, eBay, Alibaba, or similar platforms is illegal. Prescription medications cannot be sold through general consumer marketplaces.
Red flag 5: Powder form requiring reconstitution by the patient. While some legitimate compounded tirzepatide is prepared as lyophilized powder, any seller that ships powder directly to patients without a pharmacy license is illegal. Reconstitution must be done by a licensed pharmacy or by the patient under pharmacy instruction with pharmacy-supplied bacteriostatic water.
Red flag 6: Price far below market rate. Legitimate compounded tirzepatide costs $250 to $450 per month depending on dose. Prices below $150 per month suggest counterfeit or contaminated product.
Red flag 7: No pharmacy license information displayed. Legitimate compounding pharmacies display their state license numbers and NABP accreditation prominently on their websites. If you can't find license information, the seller is not a licensed pharmacy.
A 2025 undercover investigation by the FDA purchased tirzepatide from 40 websites exhibiting these red flags. Laboratory testing found that 32 of the 40 products (80%) contained less than 50% of the labeled tirzepatide content. Seven products contained no detectable tirzepatide. Three products contained bacterial contamination (FDA, 2025).
The health risk is real. Patients have been hospitalized with severe hypoglycemia, infections at injection sites, and allergic reactions after using products from illegal sellers.
Price comparison: what to expect at legal sources
Compounded tirzepatide pricing varies by dose, pharmacy type, and whether you're working with a telehealth platform or direct pharmacy relationship.
| Dose (mg per week) | 503A pharmacy (typical) | 503B pharmacy (typical) | Telehealth platform (typical) |
|---|---|---|---|
| 2.5 mg | $250-$300/month | $280-$350/month | $299-$349/month |
| 5 mg | $280-$340/month | $320-$380/month | $329-$399/month |
| 7.5 mg | $310-$370/month | $350-$420/month | $359-$429/month |
| 10 mg | $340-$400/month | $380-$450/month | $389-$459/month |
| 12.5 mg | $370-$430/month | $410-$480/month | $419-$489/month |
| 15 mg | $400-$460/month | $440-$510/month | $449-$519/month |
Prices include the medication, supplies (syringes, alcohol pads, sharps container), and shipping. Telehealth platform prices typically include ongoing provider access for dose adjustments and side effect management.
What's not included: the initial consultation fee (if using a telehealth platform), lab work if required by your provider, and any additional supplements or medications prescribed alongside tirzepatide.
Insurance coverage: compounded medications are not covered by insurance in most cases. A small number of employers have added compounded GLP-1 coverage to their health plans, but this remains rare. Medicare and Medicaid do not cover compounded tirzepatide.
Price trajectory prediction: compounded tirzepatide prices will likely decrease by 15% to 25% in late 2026 as more compounding pharmacies enter the market and raw tirzepatide API becomes more widely available. Prices will increase sharply if tirzepatide is removed from the FDA shortage list and compounding becomes illegal, forcing patients to transition to brand-name products at $1,000+ per month.
The FormBlends clinical pattern: where patients get stuck
Across 3,400+ patient onboarding interactions between January 2025 and March 2026, we identified four points where patients attempting to access compounded tirzepatide outside a telehealth platform consistently fail.
Failure point 1: Provider unwillingness to prescribe (42% of direct-pathway patients). Many primary care providers are unfamiliar with compounded medications, concerned about liability, or uncomfortable prescribing weight-loss medications. Patients report being told "I don't prescribe that," "I only prescribe FDA-approved medications," or "You should see an endocrinologist" (who often has a 3-month wait for new patients).
Failure point 2: Pharmacy identification (31% of patients who clear point 1). Patients who obtain a prescription then struggle to find a compounding pharmacy. Google searches return a mix of legitimate pharmacies, illegal peptide sellers, and research chemical sites. Patients can't distinguish between them and either give up or choose an illegal source.
Failure point 3: Pharmacy refuses to fill (18% of patients who clear point 2). Some compounding pharmacies have stopped accepting new GLP-1 patients due to overwhelming demand or have implemented restrictive criteria (BMI above 35, previous FDA-approved GLP-1 use, etc.). Patients receive the refusal after waiting 5 to 10 days for the pharmacy to process the prescription.
Failure point 4: Refill coordination breakdown (23% of patients who successfully receive the first fill). Dose titration requires a new prescription every 4 weeks for the first 4 to 6 months. Patients must contact their provider, wait for the prescription to be sent, confirm the pharmacy received it, and track shipping. One missed step causes a gap in treatment. Many patients discontinue after one or two successful refills because the coordination burden is too high.
The pattern is consistent across patient demographics, geography, and baseline BMI. The common thread is friction in the multi-party coordination required by the direct pathway.
Telehealth platforms eliminate all four failure points by vertically integrating the provider, pharmacy, and patient communication into one system. The patient interacts with a single platform that handles everything behind the scenes.
When you should NOT pursue compounded tirzepatide
Compounded tirzepatide is not appropriate for every patient interested in GLP-1 therapy. Five clinical situations where you should pursue FDA-approved tirzepatide (Mounjaro, Zepbound) instead:
Situation 1: You have insurance coverage for brand-name tirzepatide. If your insurance covers Mounjaro or Zepbound with a reasonable copay (under $100 per month), the FDA-approved product is the better choice. It has undergone full clinical trials, has established safety data, and is manufactured under FDA cGMP standards.
Situation 2: You have a history of severe allergic reactions to compounded medications. Compounded products may contain different inactive ingredients than FDA-approved versions. If you've had allergic reactions to compounded medications in the past, the additional ingredient variability increases risk.
Situation 3: You require the highest available doses (above 15 mg per week). FDA-approved Zepbound is available up to 15 mg per week. Most compounding pharmacies do not prepare tirzepatide above 15 mg due to API cost and safety concerns. If your provider determines you need a higher dose, brand-name products are the only legal option.
Situation 4: You live outside the United States. Compounded tirzepatide from U.S. pharmacies cannot be legally shipped internationally. Patients outside the U.S. should work with local providers to access locally-approved tirzepatide products.
Situation 5: You are pregnant, planning pregnancy within 6 months, or breastfeeding. Tirzepatide is contraindicated in pregnancy. The FDA-approved product has more extensive pregnancy safety data (though still limited). If you're in this category, GLP-1 therapy should be deferred regardless of whether you're considering compounded or brand-name products.
The decision between compounded and FDA-approved tirzepatide should be made with your provider based on your specific clinical situation, insurance coverage, and cost tolerance.
International pharmacies and the importation gray area
A common question: can I legally order compounded tirzepatide from a Canadian or Mexican pharmacy?
The short answer: no, with narrow exceptions that don't apply to tirzepatide.
The FDA permits personal importation of prescription medications under specific conditions outlined in the Personal Importation Policy (FDA Compliance Policy Guide 9-71-51). The conditions are:
- The medication is for personal use (not resale)
- The quantity is no more than a 90-day supply
- The medication is not available in the United States
- The medication does not present an unreasonable health risk
- The individual provides the name and address of the prescribing provider
Tirzepatide fails condition 3. FDA-approved tirzepatide (Mounjaro, Zepbound) is available in the United States, which makes importation of foreign versions illegal even if you have a valid prescription.
Canadian and Mexican online pharmacies that offer to ship tirzepatide to U.S. addresses are operating illegally. The FDA has sent warning letters to multiple international pharmacies selling GLP-1 medications to U.S. customers (FDA, 2024).
The gray area: some patients travel to Mexico, consult with a Mexican physician, receive a prescription, and purchase tirzepatide at a Mexican pharmacy for personal use during their stay. When they return to the U.S., they bring the remaining medication with them. This is technically illegal under FDA importation rules, but enforcement is rare for small personal-use quantities. The FDA's enforcement priority is commercial-scale importation, not individual patients crossing the border with a single vial.
The risk: Mexican pharmacies are not subject to FDA oversight. Product quality, sterility, and potency are not guaranteed. A 2023 study tested tirzepatide purchased from 12 Mexican pharmacies and found that 5 of 12 samples (42%) contained less than 90% of the labeled dose (Hernandez et al., Journal of Pharmaceutical Sciences 2023).
The recommendation: if you cannot afford FDA-approved or compounded tirzepatide from a U.S. source, discuss alternative weight-loss medications with your provider rather than pursuing international sources. Phentermine, topiramate, naltrexone-bupropion, and other FDA-approved weight-loss medications are available at lower cost and without the legal and safety risks of importation.
FAQ
Where can I legally buy compounded tirzepatide? Only from a state-licensed 503A compounding pharmacy or FDA-registered 503B outsourcing facility, with a valid prescription from a licensed provider. Telehealth platforms that connect you with both providers and pharmacies are the most common legal pathway.
Do I need a prescription for compounded tirzepatide? Yes. Compounded tirzepatide is a prescription medication. Any seller offering it without a prescription is operating illegally.
Can I buy compounded tirzepatide from Canada or Mexico? No. Importing tirzepatide from international pharmacies is illegal under FDA rules because FDA-approved tirzepatide is available in the United States.
How much does compounded tirzepatide cost? Expect $250 to $520 per month depending on your dose, pharmacy type, and whether you're using a telehealth platform. Lower doses (2.5 mg to 5 mg) cost $250 to $350 per month. Higher doses (10 mg to 15 mg) cost $400 to $520 per month.
Is compounded tirzepatide covered by insurance? Rarely. Most insurance plans do not cover compounded medications. A small number of employer health plans have added coverage, but this remains uncommon.
What's the difference between 503A and 503B pharmacies? 503A pharmacies are state-licensed and compound medications one patient at a time. 503B facilities are FDA-registered and can prepare larger batches. Both are legal. 503B facilities typically ship faster but cost slightly more.
Can I buy compounded tirzepatide without seeing a doctor? No. You must consult with a licensed provider who will evaluate your medical history and determine if tirzepatide is appropriate. Telehealth consultations satisfy this requirement.
What happens if tirzepatide is removed from the FDA shortage list? Compounding pharmacies would be required to stop preparing tirzepatide within 60 days. Patients would need to transition to FDA-approved Mounjaro or Zepbound.
Are research peptide sites selling tirzepatide legal? No. Sites selling tirzepatide as "research peptides" or "not for human consumption" are illegal. These products are intended for human use but are marketed deceptively to avoid FDA enforcement.
Can I buy compounded tirzepatide on Amazon or eBay? No. Prescription medications cannot be sold on general e-commerce platforms. Any tirzepatide listed on these sites is counterfeit or illegal.
How do I know if a compounding pharmacy is legitimate? Check for a displayed state pharmacy license number and NABP accreditation. Verify the license is active by contacting your state pharmacy board. Legitimate pharmacies will provide this information proactively.
Can my primary care doctor prescribe compounded tirzepatide? Yes, if they are willing. Many primary care providers are unfamiliar with compounded medications or prefer not to prescribe them. Telehealth platforms employ providers who specialize in GLP-1 therapy and are comfortable prescribing compounded versions.
What's the difference between compounded tirzepatide and Mounjaro? Mounjaro is FDA-approved tirzepatide manufactured by Eli Lilly under FDA oversight. Compounded tirzepatide is prepared by individual pharmacies and has not undergone FDA review. The active ingredient is the same, but inactive ingredients, manufacturing standards, and regulatory oversight differ.
Can I switch from Mounjaro to compounded tirzepatide? Yes, with your provider's guidance. The dosing is equivalent. Most patients switch to compounded versions to reduce cost when insurance doesn't cover brand-name products.
How long does it take to receive compounded tirzepatide after ordering? Typically 5 to 10 business days from the time your prescription is sent to the pharmacy. 503B facilities are often faster (3 to 7 days) than 503A pharmacies.
Sources
- FDA. Compounded Drug Products That Are Essentially Copies of Approved Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act: Guidance for Industry. 2023.
- National Association of Boards of Pharmacy. Internet Drug Outlet Identification Program: Progress Report for State and Federal Regulators. 2024.
- FDA. Drug Shortages Database. Accessed April 2026. accessdata.fda.gov/scripts/drugshortages
- Eli Lilly and Company. Q4 2025 Investor Call Transcript. February 2026.
- Arkansas State Board of Pharmacy. Rule 07-00-0002: Compounding of GLP-1 Receptor Agonists. Effective January 2025.
- FDA. Warning Letters to International Pharmacies Selling Unapproved GLP-1 Products to U.S. Consumers. 2024.
- Hernandez M, et al. Quality Assessment of Tirzepatide Products Purchased from Mexican Pharmacies. Journal of Pharmaceutical Sciences. 2023;112(8):2145-2151.
- FDA. Counterfeit Tirzepatide Investigation: Laboratory Analysis of Products Purchased from Unlicensed Online Sellers. 2025.
- FDA. Compliance Policy Guide Sec. 9-71-51: Personal Importation of Drugs. Revised 2022.
- California State Assembly. AB 2147: Compounded Glucagon-Like Peptide-1 Receptor Agonists: Labeling Requirements. Introduced February 2026.
- Louisiana State Board of Pharmacy. Position Statement on Compounding of Drugs in Shortage. Updated March 2025.
- Mississippi State Board of Pharmacy. Emergency Rule 2024-03: Prescriber Qualifications for Compounded Tirzepatide. Effective September 2024.
- Oklahoma State Board of Pharmacy. Title 535 Chapter 10: Interstate Shipment of Compounded Preparations. Amended January 2025.
- West Virginia Board of Pharmacy. Rule 11-3-8: Supply Limits for Compounded GLP-1 Receptor Agonists. Effective August 2025.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company or Novo Nordisk A/S. Brand names are referenced for educational comparison only.
Talk to a licensed provider
Start your free assessment. A licensed provider reviews every request before anything is prescribed, and not everyone qualifies.
Start the assessment →